Kineta Announces First Patient Dosed in Phase 1/2 Clinical Study of KVA12123 for Advanced Solid Tumors:
SEATTLE, April 17, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the presentation of new VISTA biomarker data and an update on the KVA12123 Phase 1/2 clinical trial at the American Association for Cancer Research (AACR) Annual Meeting 2023. Thierry Guillaudeux, Ph.D., Chief Scientific Officer at Kineta, presented the company’s poster unveiling the new data in the AACR poster session entitled “Biomarkers of Therapeutic Benefit 1”.
“These biomarker data provide additional compelling rationale supporting VISTA as a promising new immuno-oncology target for patients with a range of different cancers” said Dr. Guillaudeux. “A better understanding of VISTA expression in the tumor microenvironment as well as in the blood could potentially inform patient selection and treatment optimization with KVA12123 in the future”
Key results from the AACR poster presentation:
VISTA expression was detected by immunohistochemistry on tumor infiltrating immune cells, especially in non-small cell lung cancer, colorectal cancer, ovarian cancer, cervical cancers, melanoma and hepatocellular carcinomas and
VISTA expression was also detected on rare tumor cells in lung, head and neck, ovary and kidney malignancies
Multiplex IHC will be performed to confirm VISTA-positive tumor-infiltrating myeloid cells
High levels of soluble VISTA were found in colorectal, head & neck, kidney, lung and ovarian cancer patient serum samples
In the ongoing Phase 1/2 clinical trial, tumor tissues and serum samples will be collected from cancer patients prior to treatment with KVA12123 to inform the possible significance of these biomarkers
This work will help to better understand the clinical response to KVA12123 in relation to the expression level of VISTA in cancer tissues as well as in the blood and opens the possibility to consider VISTA expression as a potential biomarker for efficacy
Presentation Details:
Poster Title: VISTA expression in patients with advanced solid tumors: A potential biomarker in VISTA-101 clinical trial
Abstract Number: 972
Session Title: Biomarkers of Therapeutic Benefit 1
Session Date and Time: Sunday, April 16, 2023 at 1:30 P.M. – 5:00 P.M. Eastern Time
Location: Section 39
The poster presentation is available for viewing under Publications in the KVA12123 section of the company’s website at www.kinetabio.com.